Multiple Sclerosis Clinical Trial
— GroupCoreSITOfficial title:
Innovative Physiotherapy and Coordination of Care for People With Multiple Sclerosis: a Randomised Controlled Trial and a Qualitative Study
Verified date | February 2019 |
Source | Nordlandssykehuset HF |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project comprises a two-arm randomized controlled trial (RCT) complemented by qualitative research on innovative group-based intervention for people with Multiple Sclerosis (MS) performed in the primary health care and organized in collaboration with the services provided by a hospital's outpatient clinic. The RCT will be conducted by Nordland Hospital Trust, Bodø (NLSH), in collaboration with UiT The Arctic University of Norway (UiT) and the Norwegian Centre for Integrated Care and Telemedicine, University Hospital North Norway (NST). The overall purpose of the RCT is to demonstrate whether high-intensity individualised group-based core stability training (GroupCoreSIT) performed by physiotherapists (PTs) in the primary health care has effect on balance, walking and activities of daily living (ADL) in people with MS compared to standard care. Changes in quality of life and costs will also be studied to conclude whether the intervention is cost-effective. The qualitative study contains three parts. The first part aims to investigate users' experiences from participating in the new group intervention and in standard care. The researchers will particularly focus on reflections regarding content, feasibility, potential changes in ADL, self-management, and continuity of care. The second part will investigate how the PTs act and interact with the group while conducting the intervention, particularly how individualization is carried out, and the PTs' reflections from participating in the education and performance of the intervention. The third part explores health professionals' reflections regarding coordination of care in people with MS.
Status | Active, not recruiting |
Enrollment | 80 |
Est. completion date | December 2019 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of MS (McDonald's criteria) - EDSS 1-6.5 (minimal symptoms - able to walk 20 minimum meter with two crutches) - Minimum 14 days post exacerbation - Age >18 years - Capable to provide signed written informed consent Exclusion Criteria: - Pregnancy at enrolment - Acute orthopedic conditions affecting balance and walking |
Country | Name | City | State |
---|---|---|---|
Norway | Physiotherapy department, Nordlandssykehuset HF | Bodø |
Lead Sponsor | Collaborator |
---|---|
Nordlandssykehuset HF | Hasselt University, Helse Nord, University Hospital of North Norway, University of Memphis, University of Tromso |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Trunk Impairment Scale modified Norwegian Version | The outcome measures sitting balance | Baseline | |
Primary | Measure change in the outcome: Trunk Impairment Scale modified Norwegian Version | The outcome measures sitting balance | 1 week post intervention | |
Primary | Measure change in the outcome: Trunk Impairment Scale modified Norwegian Version | The outcome measures sitting balance | 3 months post intervention | |
Primary | Measure a change in the outcome: Trunk Impairment Scale modified Norwegian Version | The outcome measures sitting balance | 6 months post intervention | |
Primary | Mini-Balance Evaluation Systems Test | The outcome measures standing and walking balance | baseline | |
Primary | Measure a change in the outcome: Mini-Balance Evaluation Systems Test | The outcome measures standing and walking balance | 1 week post intervention | |
Primary | Measure a change in the outcome:Mini-Balance Evaluation Systems Test | The outcome measures standing and walking balance | 3 months post intervention | |
Primary | Measure a change in the outcome: Mini-Balance Evaluation Systems Test | The outcome measures standing and walking balance | 6 months post intervention | |
Secondary | 10-Meter Walk Test | The outcome measures the speed of 10 meter walking | Baseline | |
Secondary | Measure a change in the outcome: 10 Meter Walk Test | The outcome measures the speed of 10 meter walking | 1 week post intervention | |
Secondary | Measure a change in the outcome:10 Meter Walk Test | The outcome measures the speed of 10 meter walking | 3 months post intervention | |
Secondary | Measure a change in the outcome: 10 Meter Walk Test | The outcome measures the speed of 10 meter walking | 6 months post intervention | |
Secondary | 2-Minutes Walk Test | The outcome measures the distance walked in 2 minutes | Baseline | |
Secondary | Measure a change in the outcome: 2-Minutes Walk Test | The outcome measures the distance walked in 2 minutes | 1 week post intervention | |
Secondary | Measure a change in the outcome:2-MinutesWalk Test | The outcome measures the distance walked in 2 minutes | 3 months post intervention | |
Secondary | Measure a change in the outcome:2-Minutes Walk Test | The outcome measures the distance walked in 2 minutes | 6 months post intervention | |
Secondary | Rivermead Visual Gait Assessment | The outcome measures quality of movement in walking | Baseline | |
Secondary | Measure a change in the outcome:Rivermead Visual Gait Assessment | The outcome measures quality of movement in walking | 1 week post intervention | |
Secondary | Measure a change in the outcome:Rivermead Visual Gait Assessment | The outcome measures quality of movement in walking | 3 months post intervention | |
Secondary | Measure a change in the outcome:Rivermead Visual Gait Assessment | The outcome measures quality of movement in walking | 6 months post intervention | |
Secondary | MS Walking Scale-12 | a self-report form with 12 questions where limitations in various aspects of walking in the past two weeks are detected. | Baseline | |
Secondary | Measure a change in the outcome:MS Walking Scale-12 | a self-report form with 12 questions where limitations in various aspects of walking in the past two weeks are detected. | 1 week post intervention | |
Secondary | Measure a change in the outcome:MS Walking Scale-12 | a self-report form with 12 questions where limitations in various aspects of walking in the past two weeks are detected. | 3 months post intervention | |
Secondary | Measure a change in the outcome: MS Walking Scale-12 | a self-report form with 12 questions where limitations in various aspects of walking in the past two weeks are detected. | 6 months post intervention | |
Secondary | Multiple Sclerosis Impact Scale-29 | A self-report form with 29 items which records limitations in various aspects of ADL | Baseline | |
Secondary | Measure a change in the outcome:Multiple Sclerosis Impact Scale-29 | A self-report form with 29 items which records limitations in various aspects of ADL | 1 week post intervention | |
Secondary | Measure a change in the outcome:Multiple Sclerosis Impact Scale-29 | A self-report form with 29 items which records limitations in various aspects of ADL | 3 months post intervention | |
Secondary | Measure a change in the outcome:Multiple Sclerosis Impact Scale-29 | A self-report form with 29 items which records limitations in various aspects of ADL | 6 months post intervention | |
Secondary | The Patient Global Impression of Change | a self-report form that measures the subject's perceptions of change | 1 week post intervention | |
Secondary | Measure a change in the outcome: Patient Global Impression of Change | a self-report form that measures the subject's perceptions of change | 3 months post intervention | |
Secondary | Measure a change in the outcome: Patient Global Impression of Change | a self-report form that measures the subject's perceptions of change | 6 months post intervention | |
Secondary | ActiGraph activity monitor. | The outcome measures physical activity | baseline | |
Secondary | Measure a change in the outcome:ActiGraph activity monitor. | The outcome measures physical activity | 1 week post intervention | |
Secondary | Measure a change in the outcome:ActiGraph activity monitor | The outcome measures physical activity | 3 months post intervention | |
Secondary | Measure a change in the outcome:ActiGraph activity monitor | The outcome measures physical activity | 6 months post intervention | |
Secondary | Multiple Sclerosis Quality of Life-54 (MSQOL-54) | The outcome measures the participants' health related quality of life. | Baseline | |
Secondary | Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54) | The outcome measures the participants' health related quality of life. | 1 week post intervention | |
Secondary | Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54) | The outcome measures the participants' health related quality of life. | 3 months post intervention | |
Secondary | Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54) | The outcome measures the participants' health related quality of life. | 6 months post intervention | |
Secondary | Health Questionnaire (EQ-5D-3L) | The outcome measures the participants' health quality of life. | Baseline | |
Secondary | Measure a change in the outcome:Health Questionnaire (EQ-5D-3L) | The outcome measures the participants' quality of life. | 1 week post intervention | |
Secondary | Measure a change in the outcome:Health Questionnaire (EQ-5D-3L) | The outcome measures the participants' quality of life. | 3 months post intervention | |
Secondary | Measure a change in the outcome:Health Questionnaire (EQ-5D-3L) | The outcome measures the participants' quality of life. | 6 months post intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |